<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id>
<journal-title-group>
<journal-title>Dialogues in Clinical Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1294-8322</issn>
<issn pub-type="epub">1958-5969</issn>
<publisher>
<publisher-name>Les Laboratoires Servier</publisher-name>
<publisher-loc>France</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31636494</article-id>
<article-id pub-id-type="pmc">6787544</article-id>
<article-id pub-id-type="doi">10.31887/DCNS.2019.21.2/jladewig</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug discovery in psychopharmacology: from 2D models to
cerebral organoids </article-title>
<trans-title-group xml:lang="es">
<trans-title>spanish title</trans-title>
</trans-title-group>
<trans-title-group xml:lang="fr">
<trans-title>french title</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rossetti</surname>
<given-names>Andrea Carlo</given-names>
</name>
<degrees>PhD</degrees>
<aff>Author affiliations: Central Institute of Mental Health, Medical Faculty
Mannheim, Heidelberg University, Mannheim, Germany; HITBR Hector Institute for
Translational Brain Research gGmbH, Mannheim, Germany; German Cancer Research
Center (DKFZ), Heidelberg, Germany. Address for correspondence: Philipp Koch:
philipp.koch@zi-mannheim.de; Julia Ladewig: julia.ladewig@zi-mannheim.de. *All
authors contributed equally to the work.</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Koch</surname>
<given-names>Philipp</given-names>
</name>
<degrees>MD</degrees>
<aff>Author affiliations: Central Institute of Mental Health, Medical Faculty
Mannheim, Heidelberg University, Mannheim, Germany; HITBR Hector Institute for
Translational Brain Research gGmbH, Mannheim, Germany; German Cancer Research
Center (DKFZ), Heidelberg, Germany. Address for correspondence: Philipp Koch:
philipp.koch@zi-mannheim.de; Julia Ladewig: julia.ladewig@zi-mannheim.de. *All
authors contributed equally to the work.</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ladewig</surname>
<given-names>Julia</given-names>
</name>
<degrees>PhD</degrees>
<aff>Author affiliations: Central Institute of Mental Health, Medical Faculty
Mannheim, Heidelberg University, Mannheim, Germany; HITBR Hector Institute for
Translational Brain Research gGmbH, Mannheim, Germany; German Cancer Research
Center (DKFZ), Heidelberg, Germany. Address for correspondence: Philipp Koch:
philipp.koch@zi-mannheim.de; Julia Ladewig: julia.ladewig@zi-mannheim.de. *All
authors contributed equally to the work.</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="COR1">. *All authors contributed equally to the work.<label>*</label>
E-mail: <email>philipp.koch@zi-mannheim.de julia.ladewig@zi-mannheim.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<issue>2</issue>
<fpage>203</fpage>
<lpage>224</lpage>
<permissions>
<copyright-statement>© 2019, AICH – Servier Group﻿Copyright © 2019 AICH – Servier Group.
All rights reserved</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Psychiatric disorders are a heterogeneous group of mental illnesses associated with a
high social and economic burden on patients and society. The complex symptomatology
of these disorders, coupled with our limited understanding of the structural and
functional abnormalities affecting the brains of neuropsychiatric patients, has made
it difficult to develop effective medical treatment strategies. With the advent of
reprogramming technologies and recent developments in induced pluripotent stem (iPS)
cell-based protocols for differentiation into defined neuronal cultures and
3-dimensional cerebral organoids, a new era of preclinical disease modeling has begun
which could revolutionize drug discovery in psychiatry. This review provides an
overview of iPS cell-based disease models in psychiatry and how these models
contribute to our understanding of pharmacological drug action. We also propose a
refined iPSC-based drug discovery pipeline, ranging from cell-based stratification of
patients through improved screening and validation steps to more precise
psychopharmacology. </p>
</abstract>
<trans-abstract xml:lang="es">
<p>Mettre la traduction ES</p>
</trans-abstract>
<trans-abstract xml:lang="fr">
<p>Mettre la traduction FR</p>
</trans-abstract>
<kwd-group>
<kwd>
<italic>iPS cell</italic>
</kwd>
<kwd>
<italic>psychiatric disorder</italic>
</kwd>
<kwd>
<italic>drug discovery</italic>
</kwd>
<kwd>
<italic>psychopharmacology</italic>
</kwd>
<kwd>
<italic>cerebral organoid</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>An improved approach for drug discovery including cellular iPS cell-based 2D models
and cerebral organoids. The implementation of iPS cell-derived 2D and 3D culture systems
could improve several aspects of the drug discovery pipeline in psychopharmacology.
Based on prestratified patient cohorts (either by clinical manifestation or by research
domain criteria), iPS cell-based disease models should help to further stratify patients
according to molecular alterations referred to as  “molecular biotypes.“ Starting
from those molecular biotypes, iPS cell-based target identification using 2-dimensional
cultures followed by target validation applying cerebral organoids should minimize false
positives processed via the drug discovery pipeline. Finally, the improved drug
specificity could feed back into the advanced patient stratification eventually leading
 to better medical treatment specific to the molecular biotypes.</title>
<fig id="d35e127" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<title>An improved approach for drug discovery including cellular iPS cell-based 2D
models and cerebral organoids. The implementation of iPS cell-derived 2D and 3D
culture systems could improve several aspects of the drug discovery pipeline in
psychopharmacology. Based on prestratified patient cohorts (either by clinical
manifestation or by research domain criteria), iPS cell-based disease models
should help to further stratify patients according to molecular alterations
referred to as  “molecular biotypes.“ Starting from those molecular
biotypes, iPS cell-based target identification using 2-dimensional cultures
followed by target validation applying cerebral organoids should minimize false
positives processed via the drug discovery pipeline. Finally, the improved drug
specificity could feed back into the advanced patient stratification eventually
leading  to better medical treatment specific to the molecular
biotypes.</title>
</caption>
<graphic xlink:href="DCNS_21.2_fig1_Ladewig"></graphic>
</fig>
</sec>
<sec>
<title>Introduction </title>
<p>
Psychiatric diseases are devastating disorders of complex and diverse
etiology. The highly polygenic disease architecture and the variable genetic,
epigenetic, and environmental factors that contribute to the manifestation of mental
diseases have made it challenging to understand their development and pathophysiology. <sup><xref ref-type="bibr" rid="ref1">1</xref></sup>
Genome-wide association studies of large cohorts of individuals with
neuropsychiatric disorders have led to a wealth of data on the genetics of these
diseases. The proportion of patients in whom candidate causal or contributing genetic
variants are identified is, however, still very limited. Even though medication is
available to relieve symptoms and disruptive behaviors, there are often no effective
pharmacological treatments to improve the core deficits. New drug development has
stalled due to the lack of well-defined molecular targets, our restricted understanding
of the origin and the biological mechanism of psychiatric disorders, and the limitations
of current research models to investigate biological processes within the human brain
under healthy and pathologic conditions. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
Thus far, animal models such as mice have been used to provide behavioral
and molecular readouts, which allowed specification of the role of specific pathways in
psychopathology. However, animal models have several limitations: they cannot fully
reproduce the plethora of psychiatric symptoms observed in patients, nor can they
recapitulate the complex structure and function of human brains. <sup><xref ref-type="bibr" rid="ref3">3</xref></sup>
Most human post-mortem specimens represent a late stage or end point of
the disease and thus cannot provide information about how these disorders develop.
Moreover, the pharmacological treatment and the comorbidities of psychiatric disorders
represent confounding factors that make it difficult to obtain a clear and uniform
readout from post-mortem studies. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>
Lastly, biopsies of brain tissue are an invasive approach associated with
several ethical concerns, which—considering the low yield and the impossibility of
expanding post-mitotic neurons in vitro—do not represent a powerful option.  </p>
<p>
In this context, the advent of reprogramming technology and the potential
to differentiate induced pluripotent stem cells (iPS cells) into almost any desired
cellular subtype has revolutionized modern biomedicine and provides a new platform to
study human pathologies in vitro. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>
Merging iPS cell technology with human genetics offers the great
opportunity to generate unique biological information about the molecular mechanisms
involved in the pathophysiology of mental illnesses and to explore new drug targets. As
reprogrammed cells carry the genetic background of a patient, they represent a valid
platform for identifying genetic predictors of drug responses and associating cellular
abnormalities with clinical phenotypes in a human context. In recent years, iPS
cell-based models derived from psychiatric patients have recapitulated the key molecular
features of psychiatric disorders such as schizophrenia (SCZ), autism spectrum disorders
(ASDs), and bipolar (BP) disorders <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
, <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>
and have led to the first psychopharmacological screens. <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
- <sup><xref ref-type="bibr" rid="ref9">9</xref></sup>
However, classical iPS cell models based on homogeneous cellular
populations grown in the culture dish neglect the fact that the human brain is an
integrated 3-dimensional (3D) tissue structure composed of multiple cell types and
extracellular matrix. In this context, the dimensional complexity of in vitro models has
been increased with the generation of cerebral organoids derived from iPS cells. These
organoids allow us for the first time to model the 3D structure, organization,
composition, and connectivity of the human brain <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>
and thus open up the possibility of studying complex human brain
development and pathology outside the human body. Cerebral organoids resemble the early
developing human brain also with respect to gene expression programs <sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
; they exhibit human specific cellular diversity, 3D organization,
histological layers, and migration patterns (reviewed in ref 12). Today, several
protocols to generate standardized and even region-specific brain organoids are
available representing for instance the dorsal and/or ventral telencephalon, the
midbrain, the hippocampus, or the cerebellum. <sup><xref ref-type="bibr" rid="ref13">13</xref></sup>
- <sup><xref ref-type="bibr" rid="ref17">17</xref></sup>
With the advances in cell culture techniques, human cerebral organoids
have become an integral part of cell-based disease modeling of the brain (reviewed in
ref 11) and it can be assumed that this pivotal role will even increase in the future.
In this review we will summarize the most significant findings obtained with iPS
cell-based models of psychopathologies and will discuss how 2D and 3D models will
potentially revolutionize psychopharmacology; both form an experimental model point of
view as well as in the translational drug development pipeline.   </p>
</sec>
<sec>
<title>IPS cell-based psychopharmacology </title>
<p>
During the last decade, multiple psychiatric diseases have been
successfully translated to iPS cell-based in- vitro modeling, investigating alterations
associated with these disorders at a cellular or network level. Initially, most
researchers concentrated on those few known and well-described copy number variations or
mutations with high penetrance. In more recent years an increasing number of studies
have started to investigate sporadic, complex, and polygenic cases of mental disease
(for an overview of published iPS cell-based models of mental disorders, see
<italic>Table I</italic>
). IPS cell-based neuropharmacology still remains in its infancy, with most
neuropharmacological interventions being based on standard clinical pharmacological
intervention. Still, interesting observations occur from those studies linking, for
instance, clinical drug response to molecular alterations in cellular models. With the
increasing number of measurable and quantifiable phenotypes described in cellular
disease models the way will be paved for more unbiased pharmacological approaches which
may eventually lead to the identification of new classes of psychopharmacological
compounds and drugs. In the following paragraphs, we will concentrate on those iPS
cell-based models for psychiatric disease in which pharmacological interventions were
applied. For a more complete overview of iPS cell-based models of psychiatric disorders
we refer to the excellent and comprehensive reviews published on this topic. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
, <sup><xref ref-type="bibr" rid="ref3">3</xref></sup>
, <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>
  </p>
</sec>
<sec>
<title>Schizophrenia </title>
<p>
With a prevalence of almost 1% of the population, <sup><xref ref-type="bibr" rid="ref18">18</xref></sup>
schizophrenia (SCZ) is one of the most frequent major psychoses. It is a
highly polygenic psychiatric disorder characterized by a complex and variegated
symptomatology. The molecular and cellular defects that contribute to disease initiation
and/or progression are, however, still largely unknown. The first detailed
characterization of iPS cell-derived neurons from schizophrenic patients was largely
based on two families with strong familial history indicating an underlying genetic
alteration with high penetrance. Indeed, genetic characterization of these patients
revealed that one family harbored multiple copy number variations (CNVs) in
schizophrenia-associated genes such as a deletion in the <italic>NRG3</italic>
gene. This led to strong reduction of <italic>NRG3</italic>
expression which was, very interestingly, also found in the other family
even though without a clear genetic link. <italic>NRG3</italic>
is involved in multiple processes during brain development and synaptic
function. Neuronal cultures derived from these patients exhibited some striking defects
in the maturity- and activity-independent synaptic transmission of a neurotropic virus,
an epiphenomenon which indicates defects in synaptic assembly. <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>
Interestingly, the researchers observed that the antipsychotic drug
loxapine was able to alleviate the defects in virus spreading which was associated with
an increase in <italic>NRG1</italic>
expression. Other antipsychotics such as clozapine, olanzapine,
risperidone, and thiorizadine had no effect on the observed phenotype indicating a
heterogenous and complex action of loxapine besides dopamine (D1, D2, D4) receptor
antagonism. The authors also identified alterations in Wnt signaling which was further
addressed in a subsequent study using neural precursors generated from the same iPS cell
lines. This study also identified an increased susceptibility of the cells to redox
challenges as well as a defect in progenitor cell migration. In contrast to the synaptic
virus spreading phenotype, loxapine treatment did not result in any improvement of the
observed alterations. <sup><xref ref-type="bibr" rid="ref19">19</xref></sup>
A more recent study focused on STEP61, a brain-specific phosphatase
involved in the regulation of synaptic function, which was upregulated in iPS
cell-derived telencephalic excitatory neurons from two SCZ patient cohorts. STEP61
overactivation induces an increased internalization of NMDAR receptors, thus altering
the inhibitory/excitatory balance at synaptic level. Of note, the antipsychotics
loxapine and clozapine both normalized the activity of the phosphatase. <sup><xref ref-type="bibr" rid="ref20">20</xref></sup>
Considering the impairment of the GABAergic system in the etiology of SCZ,
in another study, authors derived a homogeneous culture of cortical interneurons from 14
patients in treatment with clozapine. SCZ interneurons showed decreased levels of
different protocadherins, a result in line with studies in animal models and post mortem
specimens. The dysregulated protocadherin-pathway resulted in an impairment in dendritic
arborization that was corrected by phosphokinase C inhibitor treatment. <sup><xref ref-type="bibr" rid="ref21">21</xref></sup>
  </p>
</sec>
<sec>
<title>Autism </title>
<p>
ASDs are neurodevelopmental disorders with a complex genetic background and
characterized by a plethora of symptoms related to sociability and intellectual
disabilities. <sup><xref ref-type="bibr" rid="ref22">22</xref></sup>
Considering the polygenic origin of ASD, increasing scientific attention
has recently been focused on iPS cells. Indeed, this approach allows investigation of
the complex in vitro dynamics and sheds light on the mechanisms underpinning the
different manifestation of ASD. With respect to neuropharmacological intervention,
Marchetto and collaborators found an increased cellular proliferation associated with
the increased activity of the β-catenin/BRN2 cascade in neural progenitors obtained from
a cohort of idiopathic autistic patients with clinical signs of early-age macrencephaly.
Neurons derived thereof showed signs of abnormal neurogenesis and synaptogenesis. The
neuronal phenotype could be normalized by the treatment with insulin-like growth factor
1 (IGF-1), a drug in clinical trials for ASD. <sup><xref ref-type="bibr" rid="ref23">23</xref></sup>
The same drug was also beneficial in an iPS cell model harboring a
disruption of the cation channel <italic>TRPC6</italic>
. In this model, impaired neuronal development, morphology, and function
were observed, which was partially rescued with IGF-1 and hyperforin, the major active
component of St John’s wort. <sup><xref ref-type="bibr" rid="ref24">24</xref></sup>
  </p>
<p>
Next to the idiopathic variants, several genetically defined syndromes
exist, which clinically present with similarities to the idiopathic ADS. These include
Rett syndrome (alterations in the <italic>MECP2</italic>
or <italic>CDKL5</italic>
gene), Williams-Beuren syndrome (deletion on chromosome 7q11.23), Fragile
X syndrome (expansion of a CGG triplet repeat in the <italic>FRM1 </italic>
gene) or Timothy syndrome (mutations in the <italic>CACNA1C gene</italic>
encoding the calcium channel Cav1.2 α subunit). The neuronal phenotypes of
Rett syndrome have been characterized in iPS cells derived from patients harboring
mutations in the <italic>MECP2</italic>
and <italic>CDKL5</italic>
genes. Indeed, neurons derived from Rett patients exhibited a decreased
number of excitatory synapses, a reduction in spine densities, a smaller soma size, and
electrophysiological defects, <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
phenotypes also replicated in subsequent studies. <sup><xref ref-type="bibr" rid="ref25">25</xref></sup>
, <sup><xref ref-type="bibr" rid="ref26">26</xref></sup>
Increasing <italic>MECP2</italic>
by gentamycin, a drug facilitating ribosomal read-through of premature
stop codons in mutant <italic>MECP2</italic>
as well as IGF-1 were able to increase the number of glutamatergic
synapses in this model. <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
  </p>
<p>
Interestingly, <italic>MECP2</italic>
mutant astrocytes were also shown to actively contribute to the
morphological and functional deficits of wild-type neurons, indicating a non-cell
autonomous mode of action in the disease pathogenesis. Again, IGF1 or a peptide
containing the first three amino acids of IGF1 were able to partially rescue the
observed alterations in that model. <sup><xref ref-type="bibr" rid="ref27">27</xref></sup>
Mechanistically, pharmacological IGF1 treatment was demonstrated to be
linked to an increased expression of the neuron-specific <italic>K</italic>
<sup>+</sup>
<italic>-Cl</italic>
<sup>−</sup>
<italic> cotransporter2 (KCC2)</italic>
, a downstream target of <italic>MECP2</italic>
and dysregulated in Rett syndrome-specific iPS cell-derived neurons. As a
consequence, the developmental shift in function of the neurotransmitter GABA from
excitation to inhibition which was delayed in Rett neurons was rescued towards the time
course found in control iPS cell-derived neurons. <sup><xref ref-type="bibr" rid="ref28">28</xref></sup>
In Timothy syndrome iPS cell-derived neurons, Pasca and coworkers found
that defects in calcium signaling and activity-dependent gene expression. They also
identified abnormal expression of tyrosine hydroxylase, a phenotype which could be
reverted by the atypical L-type channel blocker roscovitine. <sup><xref ref-type="bibr" rid="ref29">29</xref></sup>
With respect to Fragile X syndrome, a straightforward approach is to
identify drugs reactivating the expression of the otherwise silenced
<italic>FMR1</italic>
gene. Using iPS cell-derived neurons, Bar Nur and colleagues investigated
selected Food and Drug Administration (FDA)-approved drugs including the histone
deacetylase inhibitor trichostatin-A (TSA) and the demethylating agents 5-azacytidine
(5-azaC). They found that 5-azaC, but not TSA, upregulated <italic>FRM1</italic>
expression, even though concentrations used were beyond physiological
levels. <sup><xref ref-type="bibr" rid="ref30">30</xref></sup>
  </p>
</sec>
<sec>
<title>Mood disorders </title>
<p>
Mood disorders are characterized by recurrent fluctuations in mood state
that can lead to a dramatic reduction of the quality of life. Unipolar or major
depression (MD) is the most common mood disorder and has been predicted to become the
first cause of disability by 2030. <sup><xref ref-type="bibr" rid="ref31">31</xref></sup>
While several factors contribute to the onset of MD, the serotonergic
system seems to play a crucial role in the underpinning molecular alteration.
Consequently, the majority of the drugs prescribed to depressed patients modulate the
serotonergic system by increasing the synaptic availability of the monoamine or by
interfering with the activity of the serotonergic receptors. Citalopram, a selective
serotonin reuptake inhibitor (SSRI) has been applied to human iPS cell-derived
serotoninergic neurons and serotoninergic neurons generated by direct cell conversion.
All studies demonstrated elevated extracellular serotonin levels following SSRI
treatment of the neurons. <sup><xref ref-type="bibr" rid="ref32">32</xref></sup>
- <sup><xref ref-type="bibr" rid="ref34">34</xref></sup>
Mood swings from mania to depression are characteristic for bipolar
disorder (BPD), another disease from the mood disorder spectrum. BPD affects more than
1% of the general population, and is thus among the leading causes of disability in
young adults. <sup><xref ref-type="bibr" rid="ref35">35</xref></sup>
Lithium is currently the best-characterized drug for the treatment of BPD,
even though not all patients respond to lithium administration. In line with this,
lithium was shown to be effective in rescuing some of the defects identified in iPS
cell-derived cultures from BPD patients including calcium transients, <sup><xref ref-type="bibr" rid="ref36">36</xref></sup>
adhesion, <sup><xref ref-type="bibr" rid="ref37">37</xref></sup>
progenitor proliferation, <sup><xref ref-type="bibr" rid="ref38">38</xref></sup>
excitability, <sup><xref ref-type="bibr" rid="ref39">39</xref></sup>
, <sup><xref ref-type="bibr" rid="ref40">40</xref></sup>
or altered ratios of active/inactive modulators of dendritic spine
formation. <sup><xref ref-type="bibr" rid="ref41">41</xref></sup>
Interestingly, clinical response of patients to lithium strongly
correlated to the in vitro response with respect to the “hyperexcitability phenotype”
observed in iPS cell models allowing predictions in both directions—from the patient to
the in-vitro model and vice versa. <sup><xref ref-type="bibr" rid="ref39">39</xref></sup>
, <sup><xref ref-type="bibr" rid="ref40">40</xref></sup>
  </p>
</sec>
<sec>
<title>Cerebral organoids: 3D models of psychiatric disease </title>
<p>
Considering that many of the identified cellular phenotypes associated with
psychiatric disorders are connected to defects in progenitor proliferation, cellular
migration, or neuronal morphology and synapse formation, cerebral organoids are
attractive models to investigate the extent to which these alterations result in
architectonical or structural impairments in 3D. In recent years, cerebral organoids
have successfully been applied to studying ASD and SCZ-related pathologic phenotypes
(for an overview see <italic>Table I</italic>
). In the first reported study from 2015, the authors investigated the
structure and the transcriptomic profile of telencephalic organoids derived from
probands with idiopathic ASD, compared with unaffected first-degree family members. They
found an imbalance in the production of excitatory and inhibitory neurons caused by an
accelerated cell cycle in the GABAergic neuronal lineage. <sup><xref ref-type="bibr" rid="ref42">42</xref></sup>
Another study related to ASD showed that cerebral organoids generated from
iPS cells heterozygous for the <italic>chromodomain helicase DNA-binding protein 8
(CHD8)</italic>
gene have altered transcriptomic signatures mainly related to
neurogenesis, neuronal differentiation, forebrain development, Wnt/β-catenin signaling,
and axonal guidance. <sup><xref ref-type="bibr" rid="ref43">43</xref></sup>
The authors found a marked upregulation of <italic>TCF4</italic>
, a candidate gene potentially involved in other psychiatric disorders such
as SCZ and BP. More recently, cortical organoids were derived from a selected cohort of
ASD patients with macrocephaly. The organoids showed increased thickness of the cortical
plate and aberrant complex neurite outgrowth of newborn neurons, a phenotype in line
with the increased brain size of the patients. The authors claimed that the abnormal
growth acceleration in ASD organoids is ascribable to the alteration of specific gene
modules and the consequent altered trajectory during the early phases of cortical
development. This elegant approach confirmed the involvement of neural precursors in
ASD-related structural alterations. <sup><xref ref-type="bibr" rid="ref44">44</xref></sup>
Defects in neurogenesis and neuronal differentiation were also observed in
cerebral organoids derived from patients harboring mutations in the
<italic>MECP2</italic>
. Specifically, organoids showed structural abnormalities in ventricular
area and radial thickness, together with increased cellular proliferation and decreased
neuronal maturation. This study pointed out the role played by two specific miRNAs
(miR-199 and miR-214) in the altered phenotype, suggesting a new molecular mechanism
downstream of <italic>MECP2</italic>
mutations. <sup><xref ref-type="bibr" rid="ref45">45</xref></sup>
A study focusing on mutations of <italic>DISC-1</italic>
(disrupted-in-schizophrenia 1) and its interaction with Ndel1, a protein
involved in cell cycle control, showed that the <italic>DISC-1</italic>
/Ndel1 interaction is fundamental for the correct regulation of mitosis in
radial glial cells both in iPS cell mutant for <italic>DISC-1</italic>
and SCZ patient-derived telencephalic organoids. <sup><xref ref-type="bibr" rid="ref17">17</xref></sup>
Together, these are exciting examples demonstrating the power of the
organoid technology and pave the way for future studies implementing
psychopharmacology.  </p>
</sec>
<sec>
<title>From candidate pharmacology to drug discovery </title>
<p>
Even though most studies so far concentrated on few candidate drugs, the
feasibility of translating iPS cell models to cellular drug screening has been
demonstrated. Kauffmann and coworkers used fragile X iPS cell-derived neural precursors
to screen for the reactivation of the silenced <italic>FMR1</italic>
testing a total of 50 000 compounds. They identified a small set of
compounds showing a significant increase in <italic>FMR1</italic>
expression. <sup><xref ref-type="bibr" rid="ref46">46</xref></sup>
Another study set up a sensitive fluorescence resonance energy
transfer-based assay for the determination of FMR1 levels, testing more than 5000
compounds, among those about 4000 FDA-approved drugs. Six drugs showed an increase in
<italic>FMR1</italic>
expression, even though none of the tested drugs induced
<italic>FMR1</italic>
to clinically relevant levels. <sup><xref ref-type="bibr" rid="ref47">47</xref></sup>
A more recent publication demonstrates how iPS cells could be used to
predict drug response in case of psychiatric disorders. Comparing transcriptional
profiles of cancer cell lines, neural progenitors from healthy controls and neural
progenitor cell lines from patients with SCZ exposed to a set of 135 drugs, the authors
identified several drugs reversing post-mortem SCZ-associated transcriptomic signatures
in a cell-type and disease-specific manner. <sup><xref ref-type="bibr" rid="ref48">48</xref></sup>
Such examples nicely demonstrate how to incorporate patient-derived
material with idiosyncratic genetic compositions into larger, OMICS-based screening
approaches and thus may help to combine genetics, cell-based molecular profiling, and
pharmacology. <sup><xref ref-type="bibr" rid="ref49">49</xref></sup>
It is important to mention that with modern gene editing approaches, iPS
cells are also amenable to large-scale genetic manipulation including iCRISPR—a platform
which allows rapid, multiplexable, and inducible genome editing in human PSC raising the
possibility to introduce multiple modifications at different loci simultaneously in the
same cell. <sup><xref ref-type="bibr" rid="ref50">50</xref></sup>
For the cerebral organoid cultures, several further optimization steps are
required to broadly and effectively include this system in psychopharmacology and drug
discovery. One important issue is the question of scalability. Unlike 2D cultures,
cerebral organoids still represent heterogeneous cultures with considerable variation
within and across batches. The development of improved culture conditions including
defined extracellular matrices might facilitate the generation of more reproducible
organoid systems (reviewed in ref 51) The issue of scalability is also relevant for the
phenotypic analysis of organoids. Due to their complex and heterogeneous 3D nature,
time-consuming processing procedures such as sectioning and staining of single slides
are still standard. Advanced clearing protocols might help to develop standardized
high-throughput imaging analysis protocols and single-cell profiling might help bypass
issues with respect to cellular heterogeneity. For functional profiling, organoids with
mature neuronal circuits of consistent quality have to be developed. At some point,
increasing the complexity by including non-neuroectodermal populations such as
microglial cells <sup><xref ref-type="bibr" rid="ref52">52</xref></sup>
or a vasculature <sup><xref ref-type="bibr" rid="ref53">53</xref></sup>
, <sup><xref ref-type="bibr" rid="ref54">54</xref></sup>
might be necessary to model the complex interaction of different cell
populations in the response to pharmacological intervention.   </p>
</sec>
<sec>
<title>Reconstructing the translational drug discovery pipeline in
psychopharmacology </title>
<p>
Central nervous system (CNS) drug development is considered risky,
especially because so many promising CNS drugs failed in late-stage clinical trials,
after significant investments had been made. <sup><xref ref-type="bibr" rid="ref55">55</xref></sup>
Since 1975, only 33 drugs have been registered for psychiatry, <sup><xref ref-type="bibr" rid="ref56">56</xref></sup>
and the pharmaceutical industry is constantly cutting down research into
psychiatric drugs, <sup><xref ref-type="bibr" rid="ref57">57</xref></sup>
, <sup><xref ref-type="bibr" rid="ref58">58</xref></sup>
implying that the drug development pipeline for psychiatric drugs is
currently running dry. In the classical pipeline, molecular targets for drug discovery
are mostly defined on transformed cell lines and/or transgenic mice harboring or
overexpressing one of the few CNVs or mutations with high penetrance. Such models
insufficiently reflect the majority of psychiatric patients and the specific situation
in the human brain leading to a plethora of false-positive results which are processed
via the entire drug discovery pipeline before eventually proven ineffective in clinical
trials. One reason for the ineffectiveness of drug discovery in psychiatry might be due
to the classification of psychiatric spectrum disorders according to clinical symptoms
ignoring the recent developments towards a stratification and classification of patients
according to specific domain criteria (also called Research Domain Criteria [RDoC]). <sup><xref ref-type="bibr" rid="ref59">59</xref></sup>
Molecular studies and functional assessment of psychiatric patients
strongly suggest breaking with conventional clinical classifications and stratifying
patients into specific research domain criteria-defined “biotypes.” <sup><xref ref-type="bibr" rid="ref60">60</xref></sup>
Considering the high costs of failures in the late stages of drug
discovery, it will be important to dramatically reduce the false-positive results in
early stages of the pipeline. In this context and as outlined above, iPS cell-based
models will develop towards a pivotal role in the patient stratification and
classification processes as well as target identification and validation, eventually
leading to a more effective drug discovery pipeline. The refined drug discovery pipeline
including iPS cell-based 2D models and cerebral organoids is outlined in <italic>Figure
1</italic>
. In such a scenario, the classification of patients into heterogeneous
collectives by clinical manifestation is refined by applying research domain criteria
from unbiased clinical testing (such as MRI and functional studies). IPS cell-based
models (2D and organoids) investigating molecular and functional signatures on a
cellular or network level should lead to a further refinement into “molecular target
biotypes.” Performing high content screens directly in iPS cell-derived neural cultures
from such biotype-stratified individuals should minimize artefacts due to molecular
heterogeneity and an inadequate cellular physiology, and should at the same time provide
information about toxicology of a certain compound to predict the insurgence of side
effects in authentic human brain cells. Secondary screens based on complex cellular
models such as cerebral organoids should further reduce the number of false-positive
hits processed into the subsequent steps of drug discovery. Thus, in such a refined
pipeline, iPS cell-based systems will streamline drug development by biotype
stratification, target identification and validation eventually leading to precise
“mechanistic” pharmacological intervention and accordingly to the development of the
so-called “precision psychiatry.” <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>
  </p>
</sec>
<sec>
<title>Conclusion </title>
<p>
IPS cell-based in vitro models are promising tools to study previously
inaccessible aspects of human brain development and neuropsychiatric diseases. It is,
however, important to note that iPSC-derived brain models have their limitations with
respect to reproducing the in vivo situation of the human brain. In this context major
restrictions are the lack of maturity and limitations in the cellular composition (these
models do not contain blood vesicles or immune cells). We should also consider that each
iPSC clone represents one epigenetic variant of the given genetic background and thus
results need to be reproduced across several clones and individuals. Protocol
improvements that enable greater maturation and cellular diversity combined with
advanced readout techniques including high-throughput single cell OMICs and whole-organ
imaging will enable to investigate previously experimentally inaccessible processes
disturbed in neuropsychiatric disease and will by that be of great use for the
translational drug discovery pipeline.  </p>
<p>
<table-wrap id="d35e566" orientation="portrait" position="float"><table frame="hsides" rules="groups"><thead><tr><td colspan="1" rowspan="1">DISEASE</td><td colspan="1" rowspan="1">SAMPLE DETAILS</td><td colspan="1" rowspan="1">GENETIC ALTERATIONS</td><td colspan="1" rowspan="1">CELL TYPE</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">PHENOTYPE</td><td colspan="1" rowspan="1">PHARMACOLOGICAL TREATMENT</td><td colspan="1" rowspan="1">DOI</td></tr></thead><tbody><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">SCZ</td><td colspan="1" rowspan="1">2 patients (1 male; 1 female)</td><td colspan="1" rowspan="1">DISC-1 mutation</td><td colspan="1" rowspan="1">iPSC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Not characterized. First iPSC generated from SCZ patients.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ mp.2011.13</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Reduced connectivity, reduced neurite outgrowth, reduced synaptic
protein levels.</td><td colspan="1" rowspan="1">Loxapine increases neuronal connectivity; Clozapine, olanzapine,
risperidone, Thiorizadine have no effect.</td><td colspan="1" rowspan="1">10.1038/ nature09915</td></tr><tr><td colspan="1" rowspan="1">1 patient (woman)</td><td colspan="1" rowspan="1">Not specified - CLZ resistant</td><td colspan="1" rowspan="1">NCP</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Patient-derived NPCs show alterations in oxygen metabolism and
generation of ROS.</td><td colspan="1" rowspan="1">Valproate normalizes the levels of ROS.</td><td colspan="1" rowspan="1">10.3727/ 096368911X600957</td></tr><tr><td colspan="1" rowspan="1">3patients (2 males; 1 female)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">NPC, Glut and DA neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Impaired maturation of DA neurons; decreased levels of synapsin-1 and
PSD-95 in Glut neurons. The phenotypes were associated with mitochondrial
dysfunction.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ mp.2013.67</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">Neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Increased secretion of dopamine, norepinephrine, and epinephrine after
stimulation and increased levels of tyrosine hydroxylase when compared to
control neurons.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.stemcr.2014.08.001</td></tr><tr><td colspan="1" rowspan="1">1 patient (woman)</td><td colspan="1" rowspan="1">Not specified - CLZ resistant</td><td colspan="1" rowspan="1">NCP</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Patient derived neurospheres show increased levels of K+ and Zn+ when
compared to control cells.</td><td colspan="1" rowspan="1">Valproate reverts the K+ and ZN+ unbalance.</td><td colspan="1" rowspan="1">10.1016/ j.schres.2014.02.007</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">Hippocampal DG granule neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Deficits in DG granule neurons generation; decrease of NEUROD1, PROX1,
and TBR1; reduced neuronal activity; reduced spontaneous neurotransmitter
release.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.stemcr.2014.01.009</td></tr><tr><td colspan="1" rowspan="1">3 patients (2 males; 1 female)</td><td colspan="1" rowspan="1">15q11.2 microdeletion</td><td colspan="1" rowspan="1">NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">CYFIP1 haplosufficiency; deficits in adherens  junctions and
apical polarity.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.stem.2014.05.003</td></tr><tr><td colspan="1" rowspan="1">2 patients (1 male; 1 female)</td><td colspan="1" rowspan="1">DISC-1 mutation</td><td colspan="1" rowspan="1">FB NPCs and neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Impairment of synaptic vesicle release; functional synaptic transmission
deficits; alteration at transcriptomic level of genes related to synaptic
activity.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ nature13716</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 female)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">FB NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Aberrant cell migration; changes in cellular adhesion and oxidative
stress pathways; transcriptional  signatures related to SCZ
pathophysiology.</td><td colspan="1" rowspan="1">Clozapine and loxapine did not  rescue the defects in cell
migration.</td><td colspan="1" rowspan="1">10.1038/ mp.2014.22</td></tr><tr><td colspan="1" rowspan="1">1 patient (sex not specified)</td><td colspan="1" rowspan="1">15q11.2 deletion</td><td colspan="1" rowspan="1">iPSC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Altered dendritic morphology in iPSC-derived  neurons.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1159/ 000430916</td></tr><tr><td colspan="1" rowspan="1">1 patient (female); 1 neurotypical carrier (male)</td><td colspan="1" rowspan="1">Heterozygous intragenic  CNTNAP2 deletions</td><td colspan="1" rowspan="1">FB and Glut neurons, OPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Characterization of CNTNAP2 structural deletions  in iPSC,
neurons and OPC; Impaired neuronal  migration in patient-derived
neurospheres.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ npjschz.2015.19</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 female)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">FB NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Perturbed WNT signaling.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.biopsych.2014.12.028</td></tr><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">SCZ</td><td colspan="1" rowspan="1">Isogenic cell lines</td><td colspan="1" rowspan="1">DISC-1</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Overactivation of WNT signaling and altered  expression of FOXG1
and TBR2.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/j.celrep.2015.07.061</td></tr><tr><td colspan="1" rowspan="1">6 patients (3 males; 3 females)</td><td colspan="1" rowspan="1">22q11.2 microdeletions</td><td colspan="1" rowspan="1">Neurons  (50% Glut; 50% GABA)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Patient-derived neurons recapitulate the miRNA expression patterns
expected from 22q11.2  haploinsufficiency and are comparable to
the data obtained from autoptic specimens.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1371/ journal.pone.0132387</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">miR-19 is upregulated in and represent a key factor regulating the
expression of genes associated with abnormal migration</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1080/ 23262133.2016.1251873</td></tr><tr><td colspan="1" rowspan="1">1 patient (female) CLZ responder 1 patient (female) CLZ
non-responder</td><td colspan="1" rowspan="1">Not specified - Monozygotic twins</td><td colspan="1" rowspan="1">Glut neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Analysis of CLZ transcriptional impact on neurons derived from responder
and resistant patients.  The main differences in gene expression
were related to homophilic adhesion molecules (CDH8, DSC3 and
protocadherins).</td><td colspan="1" rowspan="1">Clozapine</td><td colspan="1" rowspan="1">10.1016/ j.schres.2016.10.012</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 female)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">FB neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Differential effect of activity–dependent changes  of gene
expression in patient-derived NPCs.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1001/ jamapsychiatry.2016.2575</td></tr><tr><td colspan="1" rowspan="1">Two cohorts: SZ1 4 patients  (3 males; 1 females);  SZ2 10 COS
patients  (6 males; 4 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">FB NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Impaired migration associated to miR-19 decrease.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.celrep.2016.03.090</td></tr><tr><td colspan="1" rowspan="1">2 patients (2 females)</td><td colspan="1" rowspan="1">22q11.2 deletion</td><td colspan="1" rowspan="1">Neurospheres</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Significant reduction of neurosphere size,  neural
differentiation efficiency, neurite outgrowth, cellular migration and the
neurogenic-to-gliogenic competence ratio.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ tp.2016.206</td></tr><tr><td colspan="1" rowspan="1">1 patient (male)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">iPSC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Not characterized. Derivation of an iPSC line from  a
CLZ-resistant schizophrenic patient.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016 /j.scr.2016.11.005</td></tr><tr><td colspan="1" rowspan="1">2 patients (1 male; 1 female)</td><td colspan="1" rowspan="1">DISC-1 deletion</td><td colspan="1" rowspan="1">NSC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Upregulation of miR-219 and downregulation of TLX expression in NSCs
derived from SCZ patient and DISC1-mutant isogenic iPSCs. SCZ NSCs
exhibit reduced cell proliferation and increased neuronal
differentiation.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ ncomms10965</td></tr><tr><td colspan="1" rowspan="1">1 patient (female);  1 neurotypical carrier (male)</td><td colspan="1" rowspan="1">Heterozygous intragenic  CNTNAP2 deletions</td><td colspan="1" rowspan="1">FB and Glut neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Increased synaptic activity in the CNTNAP2 deletion carriers.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.brainres.2015.11.009</td></tr><tr><td colspan="1" rowspan="1">4 patients (3 males; 1 female)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">NCC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Several common molecular pathways dysregulated among the unrelated cases
of SCZ analyzed. nFGFR1 signaling enlightened as a potential common
altered mechanism.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.schres.2016.12.012</td></tr><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">SCZ</td><td colspan="1" rowspan="1">5 patients  (2 males; 3 females)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">GPC, astrocytes</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">When transplanted into hypomyelinated mice, patient-derived GPC
prematurely migrate into the cortex, leading to reduced white matter
expansion and hypomyelination relative to controls. Animals show reduced
pre-pulse inhibition and abnormal behavior.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1186/ s13229-015-0048-6</td></tr><tr><td colspan="1" rowspan="1">12 patients (7 males; 5 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">In silico drug-screening approach to investigate  the
transcriptomic effect of several drugs on  patient-derived
NPC.</td><td colspan="1" rowspan="1">135 different drugs.</td><td colspan="1" rowspan="1">10.1038/ s41467-018-06515-4</td></tr><tr><td colspan="1" rowspan="1">4 patients  (3 males; 1 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">Hippocampal neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Generation of DG and CA3 neurons from SCZ  patients. DG-CA3
co-culture revealed a reduced spontaneous activity and neural network
 connectivity of patient-derived neurons.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.stem.2018.04.009</td></tr><tr><td colspan="1" rowspan="1">Two cohorts: SZ1 4 patients  (3 males; 1 females);  SZ2 9
COS patients  (6 males; 3 females)</td><td colspan="1" rowspan="1">Different SCZ-linked copy- number variants</td><td colspan="1" rowspan="1">FB and excitatory neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Increased STEP61 activity in iPSC-derived neurons from schizophrenic
patients caused increased  phosphorylation of GLUN2B. Alterations
in  GLUN2A/GLUN2B ratio is a proxy of decreased  synaptic
strength.</td><td colspan="1" rowspan="1">Clozapine, loxapine increase STEP61 phosphorylation and normalizes the
molecular alterations observed.</td><td colspan="1" rowspan="1">10.1038/ s41593-018-0313-z</td></tr><tr><td colspan="1" rowspan="1">14 patients  (males - clozapine treatment) </td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Cortical interneurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Downregulation of protocadherin gene expression. Defects in
arborization. Decreased number of  inhibitory synapses after in
vivo transplantation.</td><td colspan="1" rowspan="1">PKC inhibitor corrects arborization impairments in vitro.</td><td colspan="1" rowspan="1">10.1038/ s41593-018-0313-z</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Idiopatic ASD </td><td colspan="1" rowspan="1">1 patient  (male)</td><td colspan="1" rowspan="1">TRCP mutation</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Aberrant Ca++ signaling; decreased spine density, neurite length and
axonal outgrowth; altered  expression of SYNAPSIN-1 and
PSD-95.</td><td colspan="1" rowspan="1">IGF-1 and hyperforin normalized the deficits observed.</td><td colspan="1" rowspan="1">10.1038/ mp.2014.141</td></tr><tr><td colspan="1" rowspan="1">Healthy subject</td><td colspan="1" rowspan="1">CRISPR-Cas mutation on  CHD8 gene</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Alteration in molecular pathways related to neurodevelopment and genes
associated to ASD or  schizophrenia in mutated NPC and
neurons.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1186/ s13229-015-0048-6</td></tr><tr><td colspan="1" rowspan="1">3 patients  (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Decreased frequency of spontaneous EPSC and  decreased Na+ and K+
voltage gated currents.  Transcriptomic analysis revealed
dysregulated  processes in synaptic transmission and other
pathways known to be altered in ASD.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1007/ s12035-016-9961-8</td></tr><tr><td colspan="1" rowspan="1">8 patients (sex not specified)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">NPC show increased cellular proliferation correlated with brain size of
the donors and associated with the increased activity of the
ß-catenin/BRN2 cascade; neurons display abnormal neurogenesis, reduced
synaptogenesis and functional defects in neuronal networks.</td><td colspan="1" rowspan="1">IGF-1 corrects the deficits related to neurogenesis and
synaptogenesis.</td><td colspan="1" rowspan="1">10.1038/ mp.2016.95</td></tr><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">Idiopatic ASD</td><td colspan="1" rowspan="1">6 patients  (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Cortical neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Convergent molecular traits in idiopathic ASD affect synaptic
development and function, metabolism, and cellular molecular interactions
involving the cytoskeletal matrix; altered neuronal migration  and
electrophysiological activity.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ s41598-018-26495-1</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Rett  syndrome</td><td colspan="1" rowspan="1">1 patient  (female)</td><td colspan="1" rowspan="1">MECP2 missense mutation</td><td colspan="1" rowspan="1">iPSC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">First study to derive iPSC from a patient affected  by Rett
Syndrome.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ nmeth.1325</td></tr><tr><td colspan="1" rowspan="1">4 patients  (females)</td><td colspan="1" rowspan="1">Different MECP2 mutations</td><td colspan="1" rowspan="1">Neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Fewer synapses, reduced spine density, smaller  soma size,
altered calcium signaling and  electrophysiological defects.</td><td colspan="1" rowspan="1">IGF-1 and gentamicin rescued the altered phenotype.</td><td colspan="1" rowspan="1">10.1016/ j.cell.2010.10.016</td></tr><tr><td colspan="1" rowspan="1">1 patient  (female)</td><td colspan="1" rowspan="1">1155del32 Frameshift  mutation on MECP2 </td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">NPC carrying MeCP2 mutations have increased  susceptibility for
L1 retrotransposition.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1186/ s13229-015-0048-6</td></tr><tr><td colspan="1" rowspan="1">5 patients  (females)</td><td colspan="1" rowspan="1">Different MECP2 mutations</td><td colspan="1" rowspan="1">iPSC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Due to chromosome X reactivation authors obtained biallelic and
monoallelic mutants. Patient-derived iPSC show defects in neuronal
maturation.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1073/ pnas.1018979108</td></tr><tr><td colspan="1" rowspan="1">2 patients  (females)</td><td colspan="1" rowspan="1">CDKL5 mutations</td><td colspan="1" rowspan="1">Neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Aberrant spine morphology, as observed in the in vivo model</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ ncb2566</td></tr><tr><td colspan="1" rowspan="1">3 patients  (females)</td><td colspan="1" rowspan="1">Different MECP2 mutations</td><td colspan="1" rowspan="1">Astrocytes, GABA  interneurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Mouse hippocampal neurons show decreased soma size, neurite length and
number of terminal ends when cocultured with or when exposed to astrocyte
conditioned media. Similar morphological effects were observed when
astrocytes were co-cultured with wild-type or mutated iPSC-derived
interneurons. The effects observed were independent from the different
mutations carried by the patients.</td><td colspan="1" rowspan="1">IGF-1 and GPE (peptide containing the first 3 AA of IGF-1) have
beneficial effects on the interneuron- astrocyte cocultures.</td><td colspan="1" rowspan="1">10.1093/ hmg/ddu008</td></tr><tr><td colspan="1" rowspan="1">1 patient  (female)</td><td colspan="1" rowspan="1">MECP2e1 mutation  (deletion on exon1)</td><td colspan="1" rowspan="1">iPSC, cortical neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Defects in soma size and reduced dendritic complexity. Impaired neuronal
function was confirmed by alteration of action potential, channel
function and synaptic responsiveness.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.nbd.2015.01.001</td></tr><tr><td colspan="1" rowspan="1">1 patient  (male)</td><td colspan="1" rowspan="1">MECP2 mutation</td><td colspan="1" rowspan="1">Neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Decreased levels of KCC2, with consequent  impaired GABA
functional switch from excitation  to inhibition.</td><td colspan="1" rowspan="1">IGF-1 normalizes KCC2 levels and the altered phenotype.</td><td colspan="1" rowspan="1">10.1073/ pnas.1524013113</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Williams syndrome </td><td colspan="1" rowspan="1">1 patient  (sex not specified)</td><td colspan="1" rowspan="1">Different chromosome band 7q11.23 mutations</td><td colspan="1" rowspan="1">Cortical neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Alterations in action potentials and transcriptional dysregulations
related to neurotransmitter receptor activity, synaptic assembly, and
potassium channel complexes.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.nbd.2015.01.001</td></tr><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">Williams syndrome</td><td colspan="1" rowspan="1">5 patients  (3 males; 2 females)</td><td colspan="1" rowspan="1">Different chromosome band 7q11.23 mutations (1 male patient with partial
deletion)</td><td colspan="1" rowspan="1">NPC and cortical neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">NPC have increased doubling time and increased apoptosis, associated to
FRIZZLED9 dysfunctions. Cortical neurons show longer total dendrites,
increased number of spines and synapses and altered connectivity.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ nature19067</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Timothy syndrome </td><td colspan="1" rowspan="1">2 patients  (sex not specified)</td><td colspan="1" rowspan="1">CACNA1C mutation</td><td colspan="1" rowspan="1">Cortical neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Defects in Ca++ signaling and activity-dependent gene expression;
altered neuronal differentiation; increase release of norepinephrine and
dopamine; increased levels of TH.</td><td colspan="1" rowspan="1">Roscovitine normalizes the levels of TH.</td><td colspan="1" rowspan="1">10.1038/ nm.2576</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Fragile X syndrome </td><td colspan="1" rowspan="1">3 patients  (males)</td><td colspan="1" rowspan="1">FMR1 mutation</td><td colspan="1" rowspan="1">iPSC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Generation of iPSC lines from FXS patients and investigation of FMR1
inactivation after cell  reprogramming.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.stem.2010.04.005</td></tr><tr><td colspan="1" rowspan="1">3 patients  (males)</td><td colspan="1" rowspan="1">FMR1 mutation</td><td colspan="1" rowspan="1">iPSC and neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Fewer and shorter neurites.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1371/ journal.pone.0026203</td></tr><tr><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">FMR1 mutation</td><td colspan="1" rowspan="1">iPSC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Analysis of two chromatin remodeling drugs to  reactivate FMR1
expression in iPSC and neurons.</td><td colspan="1" rowspan="1">5-azacytidine increases the levels of FMR1 in iPSC and neurons, while
Trichostatin-A has no effect.</td><td colspan="1" rowspan="1">10.1093/ jmcb/mjs007</td></tr><tr><td colspan="1" rowspan="1">3 patients (males)</td><td colspan="1" rowspan="1">FMR1 mutation</td><td colspan="1" rowspan="1">FB neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Defective neurite initiation and extension.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1089/scd.2014.0030</td></tr><tr><td colspan="1" rowspan="1">1 patient  (sex not specified)</td><td colspan="1" rowspan="1">FMR1 mutation</td><td colspan="1" rowspan="1">NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Establishment of a high-content imaging assay  to run a
large-scale phenotypic screen aimed to identify compounds that reactivate
the silenced FMR1 gene.</td><td colspan="1" rowspan="1">HTS of 50000 compounds.</td><td colspan="1" rowspan="1">10.1177/ 1087057115588287</td></tr><tr><td colspan="1" rowspan="1">1 patient  (sex not specified)</td><td colspan="1" rowspan="1">FMR1 mutation</td><td colspan="1" rowspan="1">NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Establishment of a sensitive fluorescence resonance energy
transfer-based assay for the determination of FMRP levels in FXS patient
cells.</td><td colspan="1" rowspan="1">HTS of 4000 FDA approved  compounds.</td><td colspan="1" rowspan="1">10.5966/ sctm.2014-0278</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">BPD</td><td colspan="1" rowspan="1">3 patients  (sex not specified)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">iPSC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Expression of transcripts for membrane bound  receptors and ion
channels was significantly  increased in BP-derived neurons. BD-
derived  neurons expressed genes involved in the
 differentiation into ventral regions.</td><td colspan="1" rowspan="1">Lithium as dorsalizing agent.  Treatment significantly decrease
Ca++ transient and wave amplitude.</td><td colspan="1" rowspan="1">10.1038/ tp.2014.12</td></tr><tr><td colspan="1" rowspan="1">12 patients  (sex not specified)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">iNLC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">The authors developed an automated imaging system to detect cellular
differences between cells derived from neuronal cells derived from LiNR
patients.</td><td colspan="1" rowspan="1">Lithium</td><td colspan="1" rowspan="1">10.1038/ nature15526</td></tr><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">BPD</td><td colspan="1" rowspan="1">1 patient  (male)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">NPC and neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Upregulation of miR-34a could affect the expression of multiple genes
associated with BD. Increase of miR-34 impairs neuronal differentiation,
expression of synaptic proteins and neuronal morphology of NPC.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ mp.2014.176</td></tr><tr><td colspan="1" rowspan="1">4 patients  (2 males; 2 females)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">iPSC, NPC and neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Gene ontology pathway analyses revealed  dysregulations of RNA
metabolism, cilium assembly, WNT signaling and vesicular trafficking in
late stage neurons.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ mp.2014.176</td></tr><tr><td colspan="1" rowspan="1">2 patients  (2 males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Differential expression of genes involved in regulating proliferation,
neuronal differentiation and calcium signaling in CXCR4+ NPC.</td><td colspan="1" rowspan="1">Glycogen synthase kinase 3 inhibitor normalizes the deficits in cell
 proliferation.</td><td colspan="1" rowspan="1">10.1038/ mp.2015.7</td></tr><tr><td colspan="1" rowspan="1">3 LiR (males);  3 LiNR (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Hippocampal DG granule neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Neurons show altered expression of genes related to mitochondrial
activity, calcium signaling, and neuronal excitability. BD neurons show a
hyperexcitability phenotype.</td><td colspan="1" rowspan="1">Lithium corrects the hyperexcitability and mitochondrial dysregulations
only in LiR neurons.</td><td colspan="1" rowspan="1">10.1038/ nature15526</td></tr><tr><td colspan="1" rowspan="1">7 LiR (males); 3 LiNR (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">CRMP2 is identified as central mediator of lithium mechanism of action.
Inactive/active CRMP2 ratio  is altered only in LIR-derived
neurons and is  normalized by lithium treatment. On the contrary,
LiNR-derived neurons show no abnormalities in CRMP2 inactive status.</td><td colspan="1" rowspan="1">Lithium</td><td colspan="1" rowspan="1">10.1073/ pnas.1700111114</td></tr><tr><td colspan="1" rowspan="1">6 patients  (3 males; 3 females)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">iPSC, NPC</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">The transcriptomic analysis shows increased expression of molecules
related to neuroinflammation (e.g. NLRP2; TREM1 pathway), pointing out a
critical role in the early pathological mechanisms of BD.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ tp.2016.284</td></tr><tr><td colspan="1" rowspan="1">3 LiR (males);  3 LiNR (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Hippocampal DG granule neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Hyperexcitability when compared to controls.  LiR and
LiNR-derived neurons share excitability as common phenotype but show
several electrophysiological differences that can be successfully used
 to predict pharmacological responsiveness.</td><td colspan="1" rowspan="1">Lithium corrects the hyperexcitability of LiR neurons.</td><td colspan="1" rowspan="1">10.1038/ mp.2016.260</td></tr><tr><td colspan="1" rowspan="1">1 healthy control</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">NPC, neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">High-throughput screening of WNT/ß-catenin pathway modulators in NPC
transfected with a WNT signaling reporter construct.</td><td colspan="1" rowspan="1">1500 FDA approved compounds.</td><td colspan="1" rowspan="1">10.1177/ 1087057112456876</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">MD</td><td colspan="1" rowspan="1">Healthy subjects</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Serotonergic neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Direct conversion of human fibroblasts to  serotonergic
neurons.</td><td colspan="1" rowspan="1">Citalopram</td><td colspan="1" rowspan="1">10.1038/ mp.2015.161</td></tr><tr><td colspan="1" rowspan="1">Healthy subjects</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Serotonergic neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Direct conversion of human fibroblasts to  serotonergic
neurons.</td><td colspan="1" rowspan="1">Citalopram</td><td colspan="1" rowspan="1">10.1038/ mp.2015.101</td></tr><tr><td colspan="1" rowspan="1">2D MODELS</td></tr><tr><td colspan="1" rowspan="1">MD</td><td colspan="1" rowspan="1">Healthy subjects</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Serotonergic neurons</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Reprogramming of iPSC into serotonergic neurons.</td><td colspan="1" rowspan="1">Citalopram, tramadol</td><td colspan="1" rowspan="1">10.1038/mp.2015.7</td></tr><tr><td colspan="1" rowspan="1">Organoid Models</td></tr><tr><td colspan="1" rowspan="1">SCZ</td><td colspan="1" rowspan="1">2 patients  (males)</td><td colspan="1" rowspan="1">DISC-1 mutation</td><td colspan="1" rowspan="1">Forebrain organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">DISC1/Ndel1 interaction in regulating mitosis of  RGC; delayed
cell-cycle progression during mitosis  of RGC in human forebrain
organoids bearing  DISC-1 mutation.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1177/ 1087057112456876</td></tr><tr><td colspan="1" rowspan="1">Isogenic cell lines</td><td colspan="1" rowspan="1">DISC-1 mutation</td><td colspan="1" rowspan="1">Cerebral organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">DISC-1 mutation alters the morphology of cerebral organoids, increasing
the number of small and disorganized rosettes and inducing a decrease of
ventricle-like structures; WNT antagonist restore the observed
phenotype.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ s41398-018-0122-x</td></tr><tr><td colspan="1" rowspan="1">3 patients  (2 males; 1 females)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Cerebral organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Patient-derived organoids show abnormal  subcortical neurogenesis
and increased, premature neuronal generation; structural and molecular
 alterations observed were correlated to nuclear FGFR1
decrease.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ s41398-018-0122-x</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">ASD</td><td colspan="1" rowspan="1">4 patients  (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Telencephalic organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Perturbed transcriptomic signatures in ASD  organoids related to
cellular proliferation,  neuronal differentiation and process
outgrowth, and synaptic transmission; increase in Synapsin-1; FOXG1
interference attenuates the phenotype.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1016/ j.cell.2015.06.034</td></tr><tr><td colspan="1" rowspan="1">Healthy subject</td><td colspan="1" rowspan="1">CRISPR-CAS9 mutation of CDH8</td><td colspan="1" rowspan="1">Cerebral organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Upregulation of TCF4; altered transcriptomic  signature in
mutated organoids in pathways  related to neurogenesis, neuronal
differentiation, forebrain development, WNT/β-catenin signaling, and
axonal guidance.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1186/ s13229-017-0124-1</td></tr><tr><td colspan="1" rowspan="1">2 patients  (females)</td><td colspan="1" rowspan="1">MECP2 mutation</td><td colspan="1" rowspan="1">Cerebral organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">MeCP2 deficiency in monolayer and 3D cultures causes defective
neurogenesis and neuronal  differentiation potentially associated
to miR-199.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ mp.2017.86</td></tr><tr><td colspan="1" rowspan="1">8 patients  (males)</td><td colspan="1" rowspan="1">Not specified</td><td colspan="1" rowspan="1">Forebrain organoid</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Organoids derived from ASD patients show  increased thickness of
the cortical plate and aberrant complex neurite outgrowth of newborn
neurons. This phenotype is in line with the increased brain size of the
patients and confirms the data obtained with NPC cultures.</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">10.1038/ s41593-018-0295-x</td></tr></tbody></table></table-wrap>00000</p>
</sec>
</body>
<back>
<ack>
<p>The authors declare no financial conflicts of interest. The work was supported by the
ERA-NET NEURON, JTC 2015 Neurodevelopmental Disorders, STEM-MCD (to JL), by the German
Federal Ministry of Education and Research (BMBF) funded project EndoProtect (grant
01GQ1423B to PK). The authors also acknowledge the generous financial support by the
Hector Stiftung II. </p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandal</surname>
<given-names>MJ,</given-names>
</name>
<name>
<surname>Leppa</surname>
<given-names>V,</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Parikshak</surname>
<given-names>NN,</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH.</given-names>
</name>
</person-group>
<article-title>The road to precision psychiatry: translating geanetics into disease
mechanisms.</article-title>
<source/>
<italic>Nat Neurosci.</italic>
<year>2016</year>
<volume>19</volume>
<issue>11</issue>
<fpage>1397</fpage>
<lpage>1407</lpage>
<pub-id pub-id-type="pmid">27786179</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soliman</surname>
<given-names>MA,</given-names>
</name>
<name>
<surname>Aboharb</surname>
<given-names>F,</given-names>
</name>
<name>
<surname>Zeltner</surname>
<given-names>N,</given-names>
</name>
<name>
<surname>Studer</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Pluripotent stem cells in neuropsychiatric disorders.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2017</year>
<volume>22</volume>
<issue>9</issue>
<fpage>1241</fpage>
<lpage>1249</lpage>
<pub-id pub-id-type="pmid">28322279</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falk</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Heine</surname>
<given-names>VM,</given-names>
</name>
<name>
<surname>Harwood</surname>
<given-names>AJ,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Modeling psychiatric disorders: from genomic findings to cellular
phenotypes.</article-title>
<source/>
<italic>Mol Psychiatry. </italic>
<year>2016</year>
<volume>21</volume>
<issue>9</issue>
<fpage>1321</fpage>
<pub-id pub-id-type="pmid">27324182</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname>
<given-names>GE,</given-names>
</name>
<name>
<surname>Schrode</surname>
<given-names>N,</given-names>
</name>
<name>
<surname>Flaherty</surname>
<given-names>E,</given-names>
</name>
<name>
<surname>Brennand </surname>
<given-names>KJ.</given-names>
</name>
</person-group>
<article-title>New considerations for hiPSC-based models of neuropsychiatric
disorders.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2019</year>
<volume>24</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">29483625</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y,</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JC,</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Induced pluripotent stem cell technology: a decade of
progress.</article-title>
<source/>
<italic>Nat Rev Drug Discov.</italic>
<year>2017</year>
<volume>16</volume>
<issue>2</issue>
<fpage>115</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">27980341</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quadrato</surname>
<given-names>G,</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Arlotta</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The promises and challenges of human brain organoids as models of
neuropsychiatric disease.</article-title>
<source/>
<italic>Nat Med.</italic>
<year>2016</year>
<volume>22</volume>
<issue>11</issue>
<fpage>1220</fpage>
<lpage>1228</lpage>
<pub-id pub-id-type="pmid">27783065</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchetto</surname>
<given-names>MC,</given-names>
</name>
<name>
<surname>Carromeu</surname>
<given-names>C,</given-names>
</name>
<name>
<surname>Acab</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>A model for neural development and treatment of Rett syndrome using
human induced pluripotent stem cells.</article-title>
<source/>
<italic>Cell.</italic>
<year>2010</year>
<volume>143</volume>
<issue>4</issue>
<fpage>527</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="pmid">21074045</pub-id>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennand</surname>
<given-names>KJ,</given-names>
</name>
<name>
<surname>Simone</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Jou</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Modelling schizophrenia using human induced pluripotent stem
cells.</article-title>
<source/>
<italic>Nature.</italic>
<year>2011</year>
<volume>473</volume>
<issue>7346</issue>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">21490598</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P,</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>Pedrosa</surname>
<given-names>E,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and
characterization of its transcriptional networks in
neurodevelopment.</article-title>
<source/>
<italic>Mol Autism.</italic>
<year>2015</year>
<volume>6</volume>
<fpage>55</fpage>
<pub-id pub-id-type="pmid">26491539</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardhanareeswaran</surname>
<given-names>K,</given-names>
</name>
<name>
<surname>Mariani</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G,</given-names>
</name>
<name>
<surname>Abyzov</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Vaccarino</surname>
<given-names>FM.</given-names>
</name>
</person-group>
<article-title>Human induced pluripotent stem cells for modelling neurodevelopmental
disorders.</article-title>
<source/>
<italic>Nat Rev Neurol.</italic>
<year>2017</year>
<volume>13</volume>
<issue>5</issue>
<fpage>265</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">28418023</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>ND,</given-names>
</name>
<name>
<surname>Paşca</surname>
<given-names>SP.</given-names>
</name>
</person-group>
<article-title>Building models of brain disorders with three-dimensional
organoids.</article-title>
<source/>
<italic>Neuron.</italic>
<year>2018</year>
<volume>100</volume>
<issue>2</issue>
<fpage>389</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">30359604</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Lullo</surname>
<given-names>E,</given-names>
</name>
<name>
<surname>Kriegstein</surname>
<given-names>AR.</given-names>
</name>
</person-group>
<article-title>The use of brain organoids to investigate neural development and
disease.</article-title>
<source/>
<italic>Nat Rev Neurosci.</italic>
<year>2017</year>
<volume>18</volume>
<issue>10</issue>
<fpage>573</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="pmid">28878372</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muguruma</surname>
<given-names>K,</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K,</given-names>
</name>
<name>
<surname>Sasai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Self-organization of polarized cerebellar tissue in 3D culture of
human pluripotent stem cells.</article-title>
<source/>
<italic>Cell Rep.</italic>
<year>2015</year>
<volume>10</volume>
<issue>4</issue>
<fpage>537</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="pmid">25640179</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iefremova</surname>
<given-names>V,</given-names>
</name>
<name>
<surname>Manikakis</surname>
<given-names>G,</given-names>
</name>
<name>
<surname>Krefft</surname>
<given-names>O,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>An organoid-based model of cortical development identifies
non-cell-autonomous defects in wnt signaling contributing to Miller-Dieker
syndrome.</article-title>
<source/>
<italic>Cell Rep.</italic>
<year>2017</year>
<volume>19</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">28380362</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y,</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>AX,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Midbrain-like organoids from human pluripotent stem cells contain
functional dopaminergic and neuromelanin-producing neurons.</article-title>
<source/>
<italic>Cell Stem Cell.</italic>
<year>2016</year>
<volume>19</volume>
<issue>2</issue>
<fpage>248</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="pmid">27476966</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>X,</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>F,</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>MM,</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>HN,</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>GL.</given-names>
</name>
</person-group>
<article-title>Generation of human brain region-specific organoids using a
miniaturized spinning bioreactor.</article-title>
<source/>
<italic>Nat Protoc.</italic>
<year>2018</year>
<volume>13</volume>
<issue>3</issue>
<fpage>565</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="pmid">29470464</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>F,</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>E,</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>DISC1 Regulates neurogenesis via modulating kinetochore attachment of
Ndel1/Nde1 during mitosis.</article-title>
<source/>
<italic>Neuron.</italic>
<year>2017</year>
<volume>96</volume>
<issue>5</issue>
<fpage>1041</fpage>
<lpage>1054.e1045</lpage>
<pub-id pub-id-type="pmid">29103808</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>MJ,</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PB.</given-names>
</name>
</person-group>
<article-title>Schizophrenia.</article-title>
<source/>
<italic>Lancet.</italic>
<year>2016</year>
<volume>388</volume>
<issue>10039</issue>
<fpage>86</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">26777917</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennand</surname>
<given-names>K,</given-names>
</name>
<name>
<surname>Savas</surname>
<given-names>JN,</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Phenotypic differences in hiPSC NPCs derived from patients with
schizophrenia.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2015</year>
<volume>20</volume>
<issue>3</issue>
<fpage>361</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="pmid">24686136</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Hartley</surname>
<given-names>BJ,</given-names>
</name>
<name>
<surname>Kurup</surname>
<given-names>P,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Inhibition of STEP.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2018</year>
<volume>23</volume>
<issue>2</issue>
<fpage>271</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="pmid">27752082</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>Z,</given-names>
</name>
<name>
<surname>Noh</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Bin Kim</surname>
<given-names>W,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Dysregulated protocadherin-pathway activity as an intrinsic defect in
induced pluripotent stem cell-derived cortical interneurons from subjects with
schizophrenia.</article-title>
<source/>
<italic>Nat Neurosci.</italic>
<year>2019</year>
<volume>22</volume>
<issue>2</issue>
<fpage>229</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="pmid">30664768</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ilieva</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>Fex Svenningsen</surname>
<given-names>Å,</given-names>
</name>
<name>
<surname>Thorsen</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>TM.</given-names>
</name>
</person-group>
<article-title>Psychiatry in a dish: stem cells and brain organoids modeling autism
spectrum disorders.</article-title>
<source/>
<italic>Biol Psychiatry.</italic>
<year>2018</year>
<volume>83</volume>
<issue>7</issue>
<fpage>558</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">29295738</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchetto</surname>
<given-names>MC,</given-names>
</name>
<name>
<surname>Belinson</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Altered proliferation and networks in neural cells derived from
idiopathic autistic individuals.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2017</year>
<volume>22</volume>
<issue>6</issue>
<fpage>820</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="pmid">27378147</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griesi-Oliveira</surname>
<given-names>K,</given-names>
</name>
<name>
<surname>Acab</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>AR,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Modeling non-syndromic autism and the impact of TRPC6 disruption in
human neurons.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2015</year>
<volume>20</volume>
<issue>11</issue>
<fpage>1350</fpage>
<lpage>1365</lpage>
<pub-id pub-id-type="pmid">25385366</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricciardi</surname>
<given-names>S,</given-names>
</name>
<name>
<surname>Ungaro</surname>
<given-names>F,</given-names>
</name>
<name>
<surname>Hambrock</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95
interaction in the postsynaptic compartment and is impaired in patient
iPSC-derived neurons.</article-title>
<source/>
<italic>Nat Cell Biol.</italic>
<year>2012</year>
<volume>14</volume>
<issue>9</issue>
<fpage>911</fpage>
<lpage>923</lpage>
<pub-id pub-id-type="pmid">22922712</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djuric</surname>
<given-names>U,</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>AYL,</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>MECP2e1 isoform mutation affects the form and function of neurons
derived from Rett syndrome patient iPS cells.</article-title>
<source/>
<italic>Neurobiol Dis.</italic>
<year>2015</year>
<volume>76</volume>
<fpage>37</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">25644311</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>EC,</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>X,</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Mutant astrocytes differentiated from Rett syndrome patients-specific
iPSCs have adverse effects on wild-type neurons.</article-title>
<source/>
<italic>Hum Mol Genet.</italic>
<year>2014</year>
<volume>23</volume>
<issue>11</issue>
<fpage>2968</fpage>
<lpage>2980</lpage>
<pub-id pub-id-type="pmid">24419315</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>X,</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>KCC2 rescues functional deficits in human neurons derived from
patients with Rett syndrome.</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A.</italic>
<year>2016</year>
<volume>113</volume>
<issue>3</issue>
<fpage>751</fpage>
<lpage>756</lpage>
<pub-id pub-id-type="pmid">26733678</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paşca</surname>
<given-names>SP,</given-names>
</name>
<name>
<surname>Portmann</surname>
<given-names>T,</given-names>
</name>
<name>
<surname>Voineagu</surname>
<given-names>I,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Using iPSC-derived neurons to uncover cellular phenotypes associated
with Timothy syndrome.</article-title>
<source/>
<italic>Nat Med.</italic>
<year>2011</year>
<volume>17</volume>
<issue>12</issue>
<fpage>1657</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="pmid">22120178</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bar-Nur</surname>
<given-names>O,</given-names>
</name>
<name>
<surname>Caspi</surname>
<given-names>I,</given-names>
</name>
<name>
<surname>Benvenisty</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Molecular analysis of FMR1 reactivation in fragile-X induced
pluripotent stem cells and their neuronal derivatives.</article-title>
<source/>
<italic>J Mol Cell Biol.</italic>
<year>2012</year>
<volume>4</volume>
<issue>3</issue>
<fpage>180</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="pmid">22430918</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhi</surname>
<given-names>GS,</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ.</given-names>
</name>
</person-group>
<article-title>Depression.</article-title>
<source/>
<italic>Lancet. </italic>
<year>2018</year>
<volume>392</volume>
<issue>10161</issue>
<fpage>2299</fpage>
<lpage>2312</lpage>
<pub-id pub-id-type="pmid">30396512</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vadodaria</surname>
<given-names>KC,</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Paquola</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Generation of functional human serotonergic neurons from
fibroblasts.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2016</year>
<volume>21</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">26503761</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Z,</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>P,</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z,</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S,</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Direct conversion of human fibroblasts to induced serotonergic
neurons.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2016</year>
<volume>21</volume>
<issue>1</issue>
<fpage>62</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">26216300</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>X,</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Generation of serotonin neurons from human pluripotent stem
cells.</article-title>
<source/>
<italic>Nat Biotechnol.</italic>
<year>2016</year>
<volume>34</volume>
<issue>1</issue>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">26655496</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grande</surname>
<given-names>I,</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>Birmaher</surname>
<given-names>B,</given-names>
</name>
<name>
<surname>Vieta</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Bipolar disorder.</article-title>
<source/>
<italic>Lancet.</italic>
<year>2016</year>
<volume>387</volume>
<issue>10027</issue>
<fpage>1561</fpage>
<lpage>1572</lpage>
<pub-id pub-id-type="pmid">26388529</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>HM,</given-names>
</name>
<name>
<surname>DeLong</surname>
<given-names>CJ,</given-names>
</name>
<name>
<surname>Bame</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Transcripts involved in calcium signaling and telencephalic neuronal
fate are altered in induced pluripotent stem cells from bipolar disorder
patients.</article-title>
<source/>
<italic>Transl Psychiatry.</italic>
<year>2014</year>
<volume>4</volume>
<fpage>e375</fpage>
<pub-id pub-id-type="pmid">25116795</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JL,</given-names>
</name>
<name>
<surname>Shamah</surname>
<given-names>SM,</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>AX,</given-names>
</name>
<name>
<surname>Waldman</surname>
<given-names>ID,</given-names>
</name>
<name>
<surname>Haggarty</surname>
<given-names>SJ,</given-names>
</name>
<name>
<surname>Perlis</surname>
<given-names>RH.</given-names>
</name>
</person-group>
<article-title>Label-free, live optical imaging of reprogrammed bipolar disorder
patient-derived cells reveals a functional correlate of lithium
responsiveness.</article-title>
<source/>
<italic>Transl Psychiatry. </italic>
<year>2014</year>
<volume>4</volume>
<fpage>e428</fpage>
<pub-id pub-id-type="pmid">25158003</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madison</surname>
<given-names>JM,</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F,</given-names>
</name>
<name>
<surname>Nigam</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Characterization of bipolar disorder patient-specific induced
pluripotent stem cells from a family reveals neurodevelopmental and mRNA
expression abnormalities.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2015</year>
<volume>20</volume>
<issue>6</issue>
<fpage>703</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="pmid">25733313</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertens</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>QW,</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Differential responses to lithium in hyperexcitable neurons from
patients with bipolar disorder.</article-title>
<source/>
<italic>Nature.</italic>
<year>2015</year>
<volume>527</volume>
<issue>7576</issue>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">26524527</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stern</surname>
<given-names>S,</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>R,</given-names>
</name>
<name>
<surname>Marchetto</surname>
<given-names>MC,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Neurons derived from patients with bipolar disorder divide into
intrinsically different sub-populations of neurons, predicting the patients‘
responsiveness to lithium.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2018</year>
<volume>23</volume>
<issue>6</issue>
<fpage>1453</fpage>
<lpage>1465</lpage>
<pub-id pub-id-type="pmid">28242870</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobe</surname>
<given-names>BTD,</given-names>
</name>
<name>
<surname>Crain</surname>
<given-names>AM,</given-names>
</name>
<name>
<surname>Winquist</surname>
<given-names>AM,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Probing the lithium-response pathway in hiPSCs implicates the
phosphoregulatory set-point for a cytoskeletal modulator in bipolar
pathogenesis.</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A.</italic>
<year>2017</year>
<volume>114</volume>
<issue>22</issue>
<fpage>E4462</fpage>
<lpage>E4471</lpage>
<pub-id pub-id-type="pmid">28500272</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariani</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G,</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation
in autism spectrum disorders.</article-title>
<source/>
<italic>Cell.</italic>
<year>2015</year>
<volume>162</volume>
<issue>2</issue>
<fpage>375</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="pmid">26186191</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P,</given-names>
</name>
<name>
<surname>Mokhtari</surname>
<given-names>R,</given-names>
</name>
<name>
<surname>Pedrosa</surname>
<given-names>E,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and
characterization of its transcriptional networks in cerebral organoids derived
from iPS cells.</article-title>
<source/>
<italic>Mol Autism.</italic>
<year>2017</year>
<volume>8</volume>
<fpage>11</fpage>
<pub-id pub-id-type="pmid">28321286</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>ST,</given-names>
</name>
<name>
<surname>Paquola</surname>
<given-names>ACM,</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>S,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Pathological priming causes developmental gene network
heterochronicity in autistic subject-derived neurons.</article-title>
<source/>
<italic>Nat Neurosci.</italic>
<year>2019</year>
<volume>22</volume>
<issue>2</issue>
<fpage>243</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">30617258</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellios</surname>
<given-names>N,</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>DA,</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>SD,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>MeCP2-regulated miRNAs control early human neurogenesis through
differential effects on ERK and AKT signaling.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2018</year>
<volume>23</volume>
<issue>4</issue>
<fpage>1051</fpage>
<lpage>1065</lpage>
<pub-id pub-id-type="pmid">28439102</pub-id>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufmann</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>Schuffenhauer</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Fruh</surname>
<given-names>I,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>High-throughput screening using iPSC-derived neuronal progenitors to
identify compounds counteracting epigenetic gene silencing in Fragile X
Syndrome.</article-title>
<source/>
<italic>J Biomol Screen.</italic>
<year>2015</year>
<volume>20</volume>
<issue>9</issue>
<fpage>1101</fpage>
<lpage>1111</lpage>
<pub-id pub-id-type="pmid">26024946</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumari</surname>
<given-names>D,</given-names>
</name>
<name>
<surname>Swaroop</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>Southall</surname>
<given-names>N,</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W,</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W,</given-names>
</name>
<name>
<surname>Usdin</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>High-throughput screening to identify compounds that increase Fragile
X mental retardation protein expression in neural stem cells differentiated from
Fragile X syndrome patient-derived induced pluripotent stem cells.</article-title>
<source/>
<italic>Stem Cells Transl Med.</italic>
<year>2015</year>
<volume>4</volume>
<issue>7</issue>
<fpage>800</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="pmid">25999519</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Readhead</surname>
<given-names>B,</given-names>
</name>
<name>
<surname>Hartley</surname>
<given-names>BJ,</given-names>
</name>
<name>
<surname>Eastwood</surname>
<given-names>BJ,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Expression-based drug screening of neural progenitor cells from
individuals with schizophrenia.</article-title>
<source/>
<italic>Nat Commun.</italic>
<year>2018</year>
<volume>9</volume>
<issue>1</issue>
<fpage>4412</fpage>
<pub-id pub-id-type="pmid">30356048</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J,</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Trounson</surname>
<given-names>A,</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JC,</given-names>
</name>
<name>
<surname>Nioi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Combining hiPSCs and human genetics: major applications in drug
development.</article-title>
<source/>
<italic>Cell Stem Cell.</italic>
<year>2017</year>
<volume>21</volume>
<issue>2</issue>
<fpage>161</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="pmid">28777942</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>González</surname>
<given-names>F,</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z,</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>ZD,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>An iCRISPR platform for rapid, multiplexable, and inducible genome
editing in human pluripotent stem cells.</article-title>
<source/>
<italic>Cell Stem Cell.</italic>
<year>2014</year>
<volume>15</volume>
<issue>2</issue>
<fpage>215</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">24931489</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>X,</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>BE,</given-names>
</name>
<name>
<surname>Safaee</surname>
<given-names>H,</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>R,</given-names>
</name>
<name>
<surname>Karp </surname>
<given-names>JM,</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Engineering stem cell organoids.</article-title>
<source/>
<italic>Cell Stem Cell.</italic>
<year>2016</year>
<volume>18</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">26748754</pub-id>
</element-citation>
</ref>
<ref id="ref52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abud</surname>
<given-names>EM,</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>RN,</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>ES,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>iPSC-Derived human microglia-like cells to study neurological
diseases.</article-title>
<source/>
<italic>Neuron.</italic>
<year>2017</year>
<volume>94</volume>
<issue>2</issue>
<fpage>278</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">28426964</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansour</surname>
<given-names>AA,</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>JT,</given-names>
</name>
<name>
<surname>Bloyd</surname>
<given-names>CW,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>An in vivo model of functional and vascularized human brain
organoids.</article-title>
<source/>
<italic>Nat Biotechnol.</italic>
<year>2018</year>
<volume>36</volume>
<issue>5</issue>
<fpage>432</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="pmid">29658944</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pham</surname>
<given-names>MT,</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>KM,</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>MD,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Generation of human vascularized brain organoids.</article-title>
<source/>
<italic>Neuroreport.</italic>
<year>2018</year>
<volume>29</volume>
<issue>7</issue>
<fpage>588</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="pmid">29570159</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>SE.</given-names>
</name>
</person-group>
<article-title>Back to basics: luring industry back into
neuroscience.</article-title>
<source/>
<italic>Nat Neurosci.</italic>
<year>2016</year>
<volume>19</volume>
<issue>11</issue>
<fpage>1383</fpage>
<lpage>1384</lpage>
<pub-id pub-id-type="pmid">27786185</pub-id>
</element-citation>
</ref>
<ref id="ref56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Doef</surname>
<given-names>TF,</given-names>
</name>
<name>
<surname>Zaragoza Domingo</surname>
<given-names>S,</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>GE,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>New approaches in psychiatric drug development.</article-title>
<source/>
<italic>Eur Neuropsychopharmacol.</italic>
<year>2018</year>
<volume>28</volume>
<issue>9</issue>
<fpage>983</fpage>
<lpage>993</lpage>
<pub-id pub-id-type="pmid">30056086</pub-id>
</element-citation>
</ref>
<ref id="ref57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbott</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Novartis to shut brain research facility.</article-title>
<source/>
<italic>Nature.</italic>
<year>2011</year>
<volume>480</volume>
<issue>7376</issue>
<fpage>161</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="pmid">22158218</pub-id>
</element-citation>
</ref>
<ref id="ref58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>SE.</given-names>
</name>
</person-group>
<article-title>Revolution stalled.</article-title>
<source/>
<italic>Sci Transl Med.</italic>
<year>2012</year>
<volume>4</volume>
<issue>155</issue>
<fpage>155cm111</fpage>
</element-citation>
</ref>
<ref id="ref59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>T,</given-names>
</name>
<name>
<surname>Cuthbert</surname>
<given-names>B,</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>M,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Research domain criteria (RDoC): toward a new classification framework
for research on mental disorders.</article-title>
<source/>
<italic>Am J Psychiatry.</italic>
<year>2010</year>
<volume>167</volume>
<issue>7</issue>
<fpage>748</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="pmid">20595427</pub-id>
</element-citation>
</ref>
<ref id="ref60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandal</surname>
<given-names>MJ,</given-names>
</name>
<name>
<surname>Haney</surname>
<given-names>JR,</given-names>
</name>
<name>
<surname>Parikshak</surname>
<given-names>NN,</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Shared molecular neuropathology across major psychiatric disorders
parallels polygenic overlap.</article-title>
<source/>
<italic>Science.</italic>
<year>2018</year>
<volume>359</volume>
<issue>6376</issue>
<fpage>693</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="pmid">29439242</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>